Skip to main content
padlock icon - secure page this page is secure

In Vitro Monitoring Chlorogenic Acid in Human Urine and Serum by a Flow Injection System Exploiting the Luminol-Dissolved Oxygen Chemiluminescence Reaction

Buy Article:

$68.00 + tax (Refund Policy)

A sensitive flow injection chemiluminescence method, based on the inhibitory effect of chlorogenic acid on the reaction between luminol and dissolved oxygen, was presented for the determination of chlorogenic acid. It was found that the decrease of chemiluminescence intensity was linear with the logarithm of chlorogenic acid concentration over the range from 1.0 ng·ml-1 to 100 ng·ml-1 (r2 = 0.9978), with the detection limit of 0.3 ng·ml-1 (3). At the flow rate of 2.0 ml·min-1 for each line, a complete analytical process could be performed within 0.5 min, including sampling and washing, with a relative standard deviation lower than 3.0% (n = 5). The proposed procedure was applied successfully to determine chlorogenic acid in Flo Lonicerae for different drawn time and monitor the excretion of chlorogenic acid in human urine. It was found that the excretive amounts of chlorogenic acid in urine reached its maximum in 2 hours after intake of Flo Lonicerae tea, presenting an excretive ratio of 63.82% in 6 hours. With urinary excretion rate method, the total elimination rate constant k and half-life time t1/2 of chlorogenic acid was calculated, which were 0.7667 and 0.91 hours, respectively.

No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: Chlorogenic acid; Flo Lonicerae; chemiluminescence; dissolved oxygen; excretive; flow injection; human urine; luminol

Document Type: Research Article

Publication date: December 1, 2007

More about this publication?
  • Current Drug Metabolism aims to cover all the latest and outstanding developments in drug metabolism and disposition. The journal serves as an international forum for the publication of timely reviews in drug metabolism. Current Drug Metabolism is an essential journal for academic, clinical, government and pharmaceutical scientists who wish to be kept informed and up-to-date with the latest and most important developments. The journal covers the following areas:

    In vitro systems including CYP-450; enzyme induction and inhibition; drug-drug interactions and enzyme kinetics; pharmacokinetics, toxicokinetics, species scaling and extrapolations; P-glycoprotein and transport carriers; target organ toxicity and interindividual variability; drug metabolism and disposition studies; extrahepatic metabolism; phase I and phase II metabolism; recent developments for the identification of drug metabolites and adducts.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more